News

In the studies, both doses of ertugliflozin tested (5 mg and 15 mg daily) achieved statistically significant reductions in A1C, a measure of average blood glucose over a

J&J signed an agreement in January this year to acquire Actelion, which develops and commercializes new drugs for diseases with significant unmet medical need. With the EC approval, the

Panobinostat will be developed by Midatech for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG) as a continuation of its existing MTX110 program, and potentially for Glioblastoma (GBM).

The transaction will be funded by the Buyer Consortium through a combination of equity financing to be provided by the Buyer Consortium and debt financing, and is not

A company jointly owned by funds advised and managed by Pacific Equity Partners and The Carlyle Group will acquire the business from Valeant. iNova is engaged in the

The investigational oral agent upadacitinib was evaluated in a phase 3 clinical trial, dubbed SELECT-NEXT, in patients with moderate to severe RA who did not respond adequately to treatment with

Teva Pharmaceutical Industries announced positive results from the second Phase III HALO study of fremanezumab (TEV-48125), an investigational treatment for the prevention of migraine.  In the episodic migraine (EM)

The Prescription Drug User Fee Act (PDUFA) date is January 24, 2018. TRULANCE is a once-daily tablet approved by the FDA for the treatment of adults with chronic

Excluding Japan, Grünenthal will hold the global rights to Zomig, which is developed for the acute treatment of migraines and cluster headaches. Zomig was approved to treat migraine